{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:19:55Z","timestamp":1793834395659,"version":"4.6.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contribute to chemoresistance. Promising early-phase results were reported with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus subcutaneous azacitidine, a hypomethylating agent. In this phase 1 study, we evaluated CC-486 (oral azacitidine) plus 6 cycles of R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL or grade 3B\/transformed follicular lymphoma. CC-486 doses of 100, 150, 200, or 300 mg given 7 days before cycle 1 and on days 8-21 of cycles 1-5 were evaluated; additional patients were enrolled in the expansion phase to examine preliminary efficacy. The primary objectives were to determine the safety and the maximum tolerated dose (MTD) of CC-486 in combination with R-CHOP. The most common grade 3\/4 toxicities were hematologic, including neutropenia (62.7%) and febrile neutropenia (25.4%); grade 3\/4 nonhematologic toxicities were uncommon (&amp;lt;7%). The MTD was not established; 2 patients had dose-limiting toxicities (1 with grade 4 febrile neutropenia; 1 with grade 4 prolonged neutropenia). The recommended phase 2 dose was established as 300 mg. The overall response rate was 94.9%, with 52 patients (88.1%) achieving complete responses. With a median follow-up of 28.9 months, estimated 1- and 2-year progression-free survival rates were 84.1% and 78.6%, respectively. Overall, epigenetic priming with CC-486 before R-CHOP can be delivered with acceptable safety to patients with previously untreated intermediate- to high-risk DLBCL or grade 3B\/transformed follicular lymphoma. ClinicalTrials.gov: NCT02343536.<\/jats:p>","DOI":"10.1182\/blood.2021011679","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T19:08:15Z","timestamp":1629832095000},"page":"1147-1159","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL"],"prefix":"10.1182","volume":"139","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Reagan","sequence":"additional","affiliation":[{"name":"The Warren Alpert Medical School of Brown University, Providence, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jones","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Drew","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-6123","authenticated-orcid":false,"given":"Chengqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mulvey","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-0713","authenticated-orcid":false,"given":"Maria V.","family":"Revuelta","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0608-1350","authenticated-orcid":false,"given":"Leandro","family":"Cerchietti","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2022050218123359000_B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"21","key":"2022050218123359000_B2","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022050218123359000_B3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hon.2613","article-title":"Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP","volume":"37","author":"Mondello","year":"2019","journal-title":"Hematol Oncol."},{"issue":"9","key":"2022050218123359000_B4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov."},{"issue":"31","key":"2022050218123359000_B5","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J\u00a0Clin Oncol."},{"issue":"15","key":"2022050218123359000_B6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"PHOENIX investigators. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol."},{"issue":"31","key":"2022050218123359000_B7","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022050218123359000_B8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1385\/MO:23:2:283","article-title":"Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)","volume":"23","author":"Adde","year":"2006","journal-title":"Med Oncol."},{"issue":"6","key":"2022050218123359000_B9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol."},{"issue":"10","key":"2022050218123359000_B10","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1080\/10428190903165233","article-title":"Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab","volume":"50","author":"Chaiwatanatorn","year":"2009","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"2022050218123359000_B11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol."},{"issue":"21","key":"2022050218123359000_B12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol."},{"key":"2022050218123359000_B13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.5_2629","article-title":"ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs placebo\/R-CHOP in previously untreated abc-type diffuse large B-cell lymphoma","volume":"37","author":"Vitolo","year":"2019","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022050218123359000_B14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/asheducation-2013.1.591","article-title":"Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP","volume":"2013","author":"Cerchietti","year":"2013","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"6","key":"2022050218123359000_B15","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov."},{"issue":"20","key":"2022050218123359000_B16","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/bloodadvances.2019000210","article-title":"Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma","volume":"3","author":"Stelling","year":"2019","journal-title":"Blood Adv."},{"key":"2022050218123359000_B17","author":"Onureg\u00ae (azacitidine) [package insert]","year":"2020"},{"issue":"26","key":"2022050218123359000_B18","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2022050218123359000_B19","doi-asserted-by":"crossref","first-page":"e0135520","DOI":"10.1371\/journal.pone.0135520","article-title":"Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies","volume":"10","author":"Laille","year":"2015","journal-title":"PLoS One."},{"issue":"27","key":"2022050218123359000_B20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022050218123359000_B21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2004","journal-title":"Biometrics."},{"issue":"9","key":"2022050218123359000_B22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2022050218123359000_B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428194.2013.802784","article-title":"Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3-5 October 2012","volume":"55","author":"Meignan","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2022050218123359000_B24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10428194.2013.804917","article-title":"Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration","volume":"55","author":"Liu","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022050218123359000_B25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41467-021-21808-x","article-title":"Identifying transposable element expression dynamics and heterogeneity during development at the single-cell level with a processing pipeline scTE","volume":"12","author":"He","year":"2021","journal-title":"Nat Commun."},{"issue":"1","key":"2022050218123359000_B26","doi-asserted-by":"crossref","first-page":"e1001758","DOI":"10.1371\/journal.pbio.1001758","article-title":"Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth","volume":"12","author":"Ding","year":"2014","journal-title":"PLoS Biol."},{"issue":"10","key":"2022050218123359000_B27","first-page":"17515","article-title":"Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis","volume":"8","author":"Meng","year":"2015","journal-title":"Int J Clin Exp Med."},{"issue":"4","key":"2022050218123359000_B28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2015.265","article-title":"Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Garcia-Manero","year":"2015","journal-title":"Leukemia."},{"issue":"17","key":"2022050218123359000_B29","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-17-3716","article-title":"Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors","volume":"24","author":"Von Hoff","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2022050218123359000_B30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ajh.25216","article-title":"Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies","volume":"93","author":"Savona","year":"2018","journal-title":"Am J Hematol."},{"issue":"8","key":"2022050218123359000_B31","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials","volume":"29","author":"Maurer","year":"2018","journal-title":"Ann Oncol."},{"issue":"1","key":"2022050218123359000_B32","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1038\/s41598-021-82615-4","article-title":"Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma","volume":"11","author":"Yoshida","year":"2021","journal-title":"Sci Rep."},{"issue":"5","key":"2022050218123359000_B33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol."},{"issue":"11","key":"2022050218123359000_B34","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget."},{"issue":"5","key":"2022050218123359000_B35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia."},{"key":"2022050218123359000_B36","doi-asserted-by":"crossref","first-page":"e14555","DOI":"10.1200\/JCO.2017.35.15_suppl.e14555","article-title":"Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies","volume":"35","author":"Wa","year":"2017","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022050218123359000_B37","first-page":"E89","article-title":"p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs","volume":"110","author":"Leonova","year":"2012","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/8\/1147\/1888949\/bloodbld2021011679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/8\/1147\/1888949\/bloodbld2021011679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T18:13:20Z","timestamp":1651515200000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/8\/1147\/476663\/Phase-1-study-of-oral-azacitidine-CC-486-plus-R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011679","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}